Skip to search formSkip to main contentSkip to account menu
You are currently offline. Some features of the site may not work correctly.

Ribavirin

Known as: RTCA, Ribovirin, RBV 
A synthetic nucleoside analog of ribofuranose with activity against hepatitis C virus and other RNA viruses. Ribavirin is incorporated into viral RNA… 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2009
Highly Cited
2009
Hepatitis C virus (HCV) infects 3% of the world's population. Treatment of chronic HCV consists of a combination of PEGylated… 
  • figure 1
  • figure 2
Highly Cited
2009
Highly Cited
2009
The recommended treatment for patients with chronic hepatitis C, pegylated interferon-α (PEG-IFN-α) plus ribavirin (RBV), does… 
  • figure 1
  • figure 2
  • figure 3
Highly Cited
2009
Highly Cited
2009
BACKGROUND Treatment guidelines recommend the use of peginterferon alfa-2b or peginterferon alfa-2a in combination with ribavirin… 
  • figure 1
  • table 1
  • table 3
Highly Cited
2004
Highly Cited
2004
BACKGROUND Treatment with pegylated interferon (peginterferon) and ribavirin for 48 weeks is more effective than conventional… 
Highly Cited
2004
Highly Cited
2004
BACKGROUND Chronic hepatitis C virus (HCV) infection is a cause of major complications in persons who are also infected with the… 
  • figure 1
  • table 1
  • table 2
  • table 3
  • figure 2
Highly Cited
2002
Highly Cited
2002
BACKGROUND Treatment with peginterferon alfa-2a alone produces significantly higher sustained virologic responses than treatment… 
  • figure 1
  • figure 2
  • table 3
Highly Cited
2001
Highly Cited
2001
BACKGROUND A sustained virological response (SVR) rate of 41% has been achieved with interferon alfa-2b plus ribavirin therapy of… 
  • figure 1
  • table 1
  • table 2
  • table 3
  • figure 2
Highly Cited
2001
Highly Cited
2001
RNA viruses evolve rapidly. One source of this ability to rapidly change is the apparently high mutation frequency in RNA virus… 
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • table 1
Highly Cited
2000
Highly Cited
2000
Seeks to present a better understanding of dynamic capabilities and the resource-based view of the firm. Dynamic capabilities are… 
  • table 1
  • table 2
Highly Cited
1998
Highly Cited
1998
BACKGROUND Only 15 to 20 percent of patients with chronic hepatitis C have a sustained virologic response to interferon therapy…